亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

医学 彭布罗利珠单抗 危险系数 内科学 肿瘤科 临床终点 安慰剂 人口 临床试验 黑色素瘤 癌症 外科 置信区间 病理 免疫疗法 替代医学 环境卫生 癌症研究
作者
Alexander M.M. Eggermont,Christian U. Blank,Mario Mandalà,Georgina Venetia Long,Victoria G. Atkinson,Stéphane Dalle,Andrew Mark Haydon,Andrey Meshcheryakov,Adnan Khattak,Matteo Salvatore Carlino,Shahneen Kaur Sandhu,James Larkin,Susana Puig,Paolo A. Ascierto,Piotr Lukasz Rutkowski,Dirk Schadendorf,Rutger H.T. Koornstra,Leonel Fernando Hernandez-Aya,Anna Maria Di Giacomo,Alfons J.M. van den Eertwegh
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:22 (5): 643-654 被引量:414
标识
DOI:10.1016/s1470-2045(21)00065-6
摘要

The European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. At 15-month median follow-up, pembrolizumab improved recurrence-free survival (hazard ratio [HR] 0·57 [98·4% CI 0·43-0·74], p<0·0001) compared with placebo, leading to its approval in the USA and Europe. This report provides the final results for the secondary efficacy endpoint, distant metastasis-free survival and an update of the recurrence-free survival results.This double-blind, randomised, controlled, phase 3 trial was done at 123 academic centres and community hospitals across 23 countries. Patients aged 18 years or older with complete resection of cutaneous melanoma metastatic to lymph node, classified as American Joint Committee on Cancer staging system, seventh edition (AJCC-7) stage IIIA (at least one lymph node metastasis >1 mm), IIIB, or IIIC (without in-transit metastasis), and with an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible. Patients were randomly assigned (1:1) via a central interactive voice response system to receive intravenous pembrolizumab 200 mg or placebo every 3 weeks for up to 18 doses or until disease recurrence or unacceptable toxicity. Randomisation was stratified according to disease stage and region, using a minimisation technique, and clinical investigators, patients, and those collecting or analysing the data were masked to treatment assignment. The two coprimary endpoints were recurrence-free survival in the intention-to-treat (ITT) population and in patients with PD-L1-positive tumours. The secondary endpoint reported here was distant metastasis-free survival in the ITT and PD-L1-positive populations. This study is registered with ClinicalTrials.gov, NCT02362594, and EudraCT, 2014-004944-37.Between Aug 26, 2015, and Nov 14, 2016, 1019 patients were assigned to receive either pembrolizumab (n=514) or placebo (n=505). At an overall median follow-up of 42·3 months (IQR 40·5-45·9), 3·5-year distant metastasis-free survival was higher in the pembrolizumab group than in the placebo group in the ITT population (65·3% [95% CI 60·9-69·5] in the pembrolizumab group vs 49·4% [44·8-53·8] in the placebo group; HR 0·60 [95% CI 0·49-0·73]; p<0·0001). In the 853 patients with PD-L1-positive tumours, 3·5-year distant metastasis-free survival was 66·7% (95% CI 61·8-71·2) in the pembrolizumab group and 51·6% (46·6-56·4) in the placebo group (HR 0·61 [95% CI 0·49-0·76]; p<0·0001). Recurrence-free survival remained longer in the pembrolizumab group 59·8% (95% CI 55·3-64·1) than the placebo group 41·4% (37·0-45·8) at this 3·5-year follow-up in the ITT population (HR 0·59 [95% CI 0·49-0·70]) and in those with PD-L1-positive tumours 61·4% (56·3-66·1) in the pembrolizumab group and 44·1% (39·2-48·8) in the placebo group (HR 0·59 [95% CI 0·49-0·73]).Pembrolizumab adjuvant therapy provided a significant and clinically meaningful improvement in distant metastasis-free survival at a 3·5-year median follow-up, which was consistent with the improvement in recurrence-free survival. Therefore, the results of this trial support the indication to use adjuvant pembrolizumab therapy in patients with resected high risk stage III cutaneous melanoma.Merck Sharp & Dohme.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
6秒前
顺利秋天完成签到,获得积分10
12秒前
甜甜的黑猫完成签到,获得积分10
17秒前
32秒前
等待若魔完成签到,获得积分10
35秒前
研友_VZG7GZ的应助被落润晓采纳,获得10
38秒前
45秒前
俭朴迎荷完成签到,获得积分10
50秒前
落润晓发布了新的文献求助10
50秒前
rongrongrong完成签到,获得积分10
1分钟前
1分钟前
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
繁荣的玲完成签到,获得积分10
1分钟前
玩命的智宸完成签到,获得积分10
1分钟前
斯文败类的应助被落润晓采纳,获得10
1分钟前
水北完成签到,获得积分10
1分钟前
1分钟前
2分钟前
火星上的笑寒完成签到,获得积分10
2分钟前
传奇3的应助被落润晓采纳,获得10
2分钟前
我与我周旋久完成签到 ,获得积分10
2分钟前
2分钟前
传统完成签到,获得积分10
2分钟前
落润晓发布了新的文献求助10
2分钟前
苹果元灵完成签到,获得积分10
2分钟前
长情的小蕾完成签到,获得积分10
2分钟前
2分钟前
李爱国的应助被towind采纳,获得10
2分钟前
yjdong完成签到,获得积分10
2分钟前
2分钟前
2分钟前
nanwang完成签到,获得积分10
2分钟前
2分钟前
落润晓发布了新的文献求助10
2分钟前
3分钟前
哪块小饼干完成签到,获得积分10
3分钟前
dddj完成签到,获得积分10
3分钟前
奔跑的应助被科研通管家采纳,获得10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158789
求助须知:如何正确求助?哪些是违规求助? 9554476
关于积分的说明 21719316
捐赠科研通 7748389
什么是DOI,文献DOI怎么找? 3427080
关于科研通互助平台的介绍 2551987
邀请新用户注册赠送积分活动 2471354